CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for VIVUS, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

VIVUS, Inc.
900 E Hamilton Ave
Suite 550
Phone: (650) 934-5200p:650 934-5200 Campbell, CA  95008-0643  United States Fax: (302) 655-5049f:302 655-5049

This company ceased filing statements with the SEC on 1/8/2021.
This company is no longer actively traded on any major stock exchange.

Business Summary
VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-YesYesYes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/202012/31/2019YesYesYes--

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board David Y.Norton 68 9/12/2014 7/19/2013
Chief Executive Officer, Director John P.Amos 53 4/30/2018 4/30/2018
Chief Financial Officer, Senior Vice President, Chief Accounting Officer Mark K.Oki 51 2/21/2019 10/19/2015
7 additional Officers and Directors records available in full report.

Business Names
Business Name
Vivus B.V.
VIVUS BV
Vivus Digital Health Corporation
4 additional Business Names available in full report.

General Information
Outstanding Shares: 17,867,697 (As of 4/30/2020)
Shareholders: 1,438
Stock Exchange: OTC
Federal Tax Id: 943136179
Fax Number: (302) 655-5049
Email Address: webmaster@vivus.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, December 30, 2023